DE2106156A1 - !Arzneimittel zur Senkung des Serum-Cholesterinspiegels - Google Patents
!Arzneimittel zur Senkung des Serum-CholesterinspiegelsInfo
- Publication number
- DE2106156A1 DE2106156A1 DE19712106156 DE2106156A DE2106156A1 DE 2106156 A1 DE2106156 A1 DE 2106156A1 DE 19712106156 DE19712106156 DE 19712106156 DE 2106156 A DE2106156 A DE 2106156A DE 2106156 A1 DE2106156 A1 DE 2106156A1
- Authority
- DE
- Germany
- Prior art keywords
- molecular weight
- diet
- active compound
- groups
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims description 35
- 239000003814 drug Substances 0.000 title claims description 26
- 229940079593 drug Drugs 0.000 title claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 29
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 241000208199 Buxus sempervirens Species 0.000 claims 1
- 235000005911 diet Nutrition 0.000 description 50
- 230000037213 diet Effects 0.000 description 50
- 230000000052 comparative effect Effects 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 21
- 241000700159 Rattus Species 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000260 hypercholesteremic effect Effects 0.000 description 2
- 230000000871 hypocholesterolemic effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010871 livestock manure Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940118683 ox bile extract Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3591670 | 1970-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2106156A1 true DE2106156A1 (de) | 1972-01-27 |
Family
ID=10382978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712106156 Pending DE2106156A1 (de) | 1970-07-24 | 1971-02-10 | !Arzneimittel zur Senkung des Serum-Cholesterinspiegels |
Country Status (8)
| Country | Link |
|---|---|
| BE (1) | BE762490A (enExample) |
| CA (1) | CA958335A (enExample) |
| DE (1) | DE2106156A1 (enExample) |
| FR (1) | FR2099561B1 (enExample) |
| GB (1) | GB1306976A (enExample) |
| IE (1) | IE34876B1 (enExample) |
| NL (1) | NL7101175A (enExample) |
| ZA (1) | ZA71279B (enExample) |
-
1970
- 1970-07-24 GB GB3591670A patent/GB1306976A/en not_active Expired
-
1971
- 1971-01-14 IE IE41/71A patent/IE34876B1/xx unknown
- 1971-01-18 ZA ZA710279A patent/ZA71279B/xx unknown
- 1971-01-28 NL NL7101175A patent/NL7101175A/xx unknown
- 1971-02-01 CA CA104,178A patent/CA958335A/en not_active Expired
- 1971-02-01 FR FR7103209A patent/FR2099561B1/fr not_active Expired
- 1971-02-03 BE BE762490A patent/BE762490A/xx unknown
- 1971-02-10 DE DE19712106156 patent/DE2106156A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA958335A (en) | 1974-11-26 |
| IE34876L (en) | 1972-01-24 |
| BE762490A (fr) | 1971-08-03 |
| FR2099561B1 (enExample) | 1974-08-23 |
| GB1306976A (en) | 1973-02-14 |
| ZA71279B (en) | 1972-02-23 |
| NL7101175A (enExample) | 1972-01-26 |
| IE34876B1 (en) | 1975-09-03 |
| FR2099561A1 (enExample) | 1972-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69821553T2 (de) | Granulatzubereitung enthaltend Simethicon und granuliertes wasserfreies Calciumphosphat | |
| DE69009684T2 (de) | Pharmazeutische Zusammensetzungen zur Behandlung gastrointestinaler Störungen. | |
| DE3856018T2 (de) | Verwendung von einer Disaccharidpolysulfat-Aluminium Verbindung zur Herstellung eines Medikaments zur Behandlung von HÄMORRHOIDEN und zur Wundheilung | |
| DE2332484C2 (de) | Arzneimittel mit verzögerter Wirkstoffabgabe | |
| DE69907606T2 (de) | Zusammensetzung, die Panax pseudo ginseng und Eucommiae ulmoides enthält | |
| DE202004021169U1 (de) | Pharmazeutische Formulierung, die Lanthanverbindungen enthält | |
| CH653891A5 (de) | Mittel fuer die orale verabreichung an einen menschen und/oder ein saeugetier. | |
| DE69128760T2 (de) | Antidiarrhoeika | |
| DE69615984T2 (de) | Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen | |
| WO2009036906A1 (de) | Zusammensetzung mit wirkstoffkombination aus einem laxans und einem entschäumer zur behandlung von obstipation | |
| DE3040780A1 (de) | Pharmazeutische zusammensetzung zur behandlung von diabetes und verfahren zu deren herstellung | |
| DE3001357C2 (de) | Granuliertes Abführmittel auf der Basis von Plantagosamen und Sennesfrüchten und Verfahren zur Herstellung desselben | |
| EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE69525348T2 (de) | Medikament gegen myotonische dystrophie | |
| DE2106156A1 (de) | !Arzneimittel zur Senkung des Serum-Cholesterinspiegels | |
| DE3315607A1 (de) | Verwendung von albendazol in oraler verabreichungsform bei der bekaempfung von echinokokkose des menschen und arzneimittel | |
| DE69103294T2 (de) | Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten. | |
| EP1383523A2 (de) | Kombinationspräparat zur behandlung des diabetes mellitus | |
| EP3090638B1 (de) | Nahrungsergänzung zur behandlung von vitamin-d3-mangelerscheinungen | |
| DE2033629C3 (de) | Oral verabreichbares Mittel zur Erniedrigung des Serum-Lipidspiegels bei Menschen | |
| EP0002803B1 (de) | Cis-(3,3,5)-Trimethylcyclohexanol zur Verwendung bei der Behandlung von Galleleiden | |
| DE60020888T2 (de) | Zusatz aus kräutern zur behandlung von kognitiven störungen aufgrund von östrogenverlust | |
| DE60206467T2 (de) | Entgiftende phytotherapeutische Zusammensetzung aus zwei Pflanzenextrakten und Verfahren zu deren Herstellung | |
| EP0129822A2 (de) | Neue pharmazeutische Zubereitungen mit Antitumorwirkung | |
| DE2401449A1 (de) | Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen |